Current status and perspectives of regulatory T cell-based therapy

作     者：Guojun Qu Jieqiong Chen Yangyang Li Yaqin Yuan Rui Liang Bin Li Guojun Qu;Jieqiong Chen;Yangyang Li;Yaqin Yuan;Rui Liang;Bin Li

作者机构：Shanghai Institute of ImmunologyDepartment of Immunology and MicrobiologyShanghai Jiao Tong University School of MedicineShanghai Jiao Tong UniversityShanghai 200025China Shanghai Affinity Biopharmaceutical Co.Ltd.781 Cailun RoadShanghai 201203China Unit of Immune and Metabolic RegulationSchool of Life Science and TechnologyShanghaiTech UniversityShanghai 201210China 

出 版 物：《Journal of Genetics and Genomics》 (遗传学报（英文版）)

年 卷 期：2022年第49卷第7期

页      面：599-611页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1010[医学-医学技术（可授医学、理学学位）] 100215[医学-康复医学与理疗学] 10[医学] 

基　　金：supported by National Science Foundation for Distinguished Young Scholars (31525008) National Natural Science Foundation of China (32130041, 81830051, 31961133011) The National Key Research and Development Project (2019YFA0906102) Shanghai Collaborative Innovation Center of Cellular Homeostasis Regulation and Human Diseases Shanghai Jiao Tong University (SJTU)-The Chinese University of Hong Kong (CUHK) Joint Research Collaboration Fund the Fundamental Research Funds for Central Universities Innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20210601) 

主　　题：Regulatory T cell FOXP3 Chimeric antigen receptor Cell therapy CRISPR-Based gene editing mRNA-based therapy 

摘      要：The CD4FOXP3regulatory T(Treg)cells are essential for maintaining immune homeostasis in healthy *** from clinical trials of Treg cell-based therapies in patients with graft versus host disease(GVHD),type 1 diabetes(T1D),liver transplantation,and kidney transplantation have demonstrated that adoptive transfer of Treg cells is emerging as a promising strategy to promote immune *** we provide an overview of recent progresses and current challenges of Treg cell-based *** summarize the completed and ongoing clinical trials with human Treg ***,a few of the chimeric antigen receptor(CAR)-Treg cell therapies are currently undergoing clinical ***,we describe the new strategies for engineering Treg cells used in preclinical ***,we envision that the use of novel synthetic receptors,metabolic regulators,combined therapies,and in vivo generated antigen-specific or engineered Treg cells through the delivery of modified mRNA and CRISPR-based gene editing will further promote the advances of next-generation Treg cell therapies.